|
|---|
|
October 11, 2012 - Attached is an opinion from the Federal Circuit affirming Judge Chesler’s denial of Roche’s motion for a preliminary injunction. FLH represents Mylan Inc. and Mylan Pharmaceuticals Inc., who are defendants/appellees in the case against Hoffmann-La Roche Inc. and Genentech, Inc. The district court’s denial allowed Mylan to launch its generic ibandronate sodium 150-mg monthly tablets, which are used in treating and preventing osteoporosis
|
|
NEW YORK, NY July 21, 2011 - Frommer Lawrence & Haug LLP is pleased to announce that on July 21, 2011, a unanimous Federal Circuit panel affirmed a finding of summary judgment of noninfringement for its client Paddock Laboratories, Inc. against Duramed Pharmaceuticals, Inc. (now known as Teva Women’s Health).
|
|
June 1, 2010, Judge Leonard B. Sand of the U.S. District Court for the Southern District of New York ruled in favor of FLH client, Paddock Laboratories, Inc. (“Paddock”), by granting summary judgment of noninfringement of Duramed Pharmaceuticals, Inc.’s (“Duramed”) (n/k/a Teva Women’s Health) U.S. Patent No. 5,908,638.
|
|
April 9, 2010, The Ninth Circuit Court of Appeals on Wednesday affirmed an award of $1.7 million to Lucky Break Wishbone Corporation over retailer Sears, Roebuck and Co. and advertising giant Young & Rubicam, Inc. The decision was seen as a victory for U.S.-based intellectual property rights and small business competing in a global environment.
|
|
February 25, 2010, In denying a preliminary injunction motion filed by The Mainstreet Collection to enforce an alleged trade dress covering monogrammed, polka dot portfolios, Kirkland’s, a leading specialty retailer of home décor, may continue to market and sell its products.
|
|
The U.S. Patent and Trademark Office (USPTO) estimates that the average time for a patent to issue is 22 months, although this may extend to over 48 months based on the invention’s field of technology (e.g., biotechnology patent applications typically take longer to issue). To this end, the USPTO offers an accelerated examination procedure that allows an application to advance out of turn for examination.
|
|
September 23, 2009, In recent years, the Eastern District of Texas has become a hotbed for patent litigation, receiving attention from both the general media and intellectual property trade press in this regard. Whether or not the case, many perceive that this forum is favorable for patentees.
|
|
September 17, 2009, Frommer Lawrence & Haug LLP announced that it has filed a Brief with the U.S. Court of Appeals for the Federal Circuit in conjunction with its representation of Shire LLC (“Shire”) against Sandoz, Inc. (“Sandoz”) in an interlocutory appeal from the U.S. District Court for the District of Colorado
|
|
September 9, 2009, FLH maintains an active and diverse pro bono effort, including a practice led by partner Richard Parke that involves assisting United States service members in various ways.
|
|
July 14, 2009, Frommer Lawrence & Haug LLP obtained a favorable settlement on behalf of its client, Shire LLP ("Shire"). The settlement put to an end a years-long litigation with Corepharma LLP ("Corepharma") in connection with Corepharma's Alleviated New Drug Application and its attempt to market generic versions of Shire's Carbatrol® for the treatment of epilepsy and trigeminal neuralgia.
|
|
On April 4, 2007, the United States District Court for the District of New Jersey granted summary judgment in favor of FLH client Par Pharmaceutical Companies, Inc. and its subsidiaries Kali Laboratories Inc. and Par Pharmaceutical, Inc.
|
|
In February 2007, the federal court in New Jersey granted FLH client Shire Laboratories Inc.’s motion to dismiss the defendant’s counterclaim of non-infringement of a Shire patent for lack of subject matter jurisdiction. The decision streamlined the case and removed that patent from issue, a patent that Shire had chosen not to assert. The case concerns an attempt to commercialize a generic version of Shire’s Carbatrol® drug product, indicated for the treatment of epilepsy and trigeminal neuralgia, before the expiration of the patents that cover Carbatrol.
|
|
FLH’s successful representation of Shire Laboratories Inc. since February 2003 lead to the August 2006 settlements of Hatch-Waxman litigations pending in the Southern District of New York, involving three Shire patents and defendant Barr Laboratories’ efforts to market generic versions of Shire’s Adderall XR® Attention Deficit Hyperactivity Disorder (“ADHD”) products.
|
|
New York, -Frommer Lawrence & Haug LLP announced on March 29, 2006 that the Second Circuit affirmed their client Tokyo Electron Arizona, LLC's $11.4 million judgment against Discreet Industries Corp. and Ovadia Meron. The Second Circuit affirmed the jury's verdict and specifically rejected the appellants' argument that the damage award was duplicative.
|
|
In August 2005, the federal court in New Jersey granted summary judgment and ruled that FLH client Purepac Pharmaceutical Co. did not infringe a patent related to the widely prescribed anti-epilepsy drug Neurontin (gabapentin). That victory follows earlier summary judgment victories on other patents related to Neurontin.
|
|
FLH Attoneys Prevail in November 2004 Decision in Section 291 Judicial Interference.
|
|
New York, -Frommer Lawrence & Haug LLP announced on April 1, 2004 that it had won a complex trade secrets jury trial for its long-time client Tokyo Electron Limited's subsidiary Tokyo Electron Arizona (TAZ).
|
|
On January 20, the U.S. Court of Appeals for the District of Columbia Circuit issued a 22-page decision that preserves the 180-day market exclusivity award to FLH client Purepac Pharmaceutical Co. for Purepac's generic formulation of the widely-prescribed anti-epilepsy drug Neurontin (gabapentin).
|
|
Frommer Lawrence & Haug successfully settled a Hatch-Waxman litigation for value for a generic pharmaceutical company, including an authorized generic escitalopram opportunity, and alternative early-launch opportunity, and compensation for attorney's fees.
|